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Human cancers are driven by genetic mutations which cause aberrant activation of pro-growth pathways. 
Although cancers are uniquely dependent on the pro-growth signaling from oncogenic pathways, efforts to 
directly target these have been largely unsuccessful. One of the most common and drug resistant oncogenic 
drivers in colon cancer is the GTPase KRAS. It has been shown that colon cancers with KRAS driver mutations 
are also ‘addicted’ to proteins outside of the KRAS pathway due to aberrant re-wiring of cell signaling. A 
number of genes with a synthetic lethal relationship to mutant KRAS have been previously identified by RNAi 
screens. MicroRNAs (miRNAs) are important post-transcriptional regulators of gene expression, and their 
expression is frequently dysregulated in cancers. Recently, we have used an innovative functional miRNA 
screening approach to identify miRNAs that inhibit the survival of KRAS-mutant cells but not KRAS-wild-type 
cells. MiR-126 was one of the miRNAs that displayed this selective effect. We found that miR-126 induced 
synthetic lethality in KRAS-Mutant cells via the down-regulation of the polo-like kinase signaling network and a 
number of genes specifically necessary for the growth of KRAS-Mutant tumors. This study offers a new way 
forward for exploiting the regulatory power of miRNAs to specifically target aberrant cell signaling in cancer. 
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In studies of model organism genetics, mutations which 
are individually harmless may result in a lethal phenotype 
when combined. This combinatorial manifestation of 
loss-of-function is termed ‘synthetic lethality,’ with synthetic 
being used in the Greek sense, meaning ‘placed together’ [1]. 
This phenomenon is a result of phenotypic robustness in 
biological systems conferred by redundant or parallel 
pathways meant to buffer genetic variation and thereby 
reduce the chances that a mutation will have adverse effects 
on fitness [2]. In cancer, this phenotypic robustness is often 
lost, and instead cancers depend on a single oncogenic 
pathway for sustaining malignant growth [3]. For example, 
the monomeric GTPase KRAS is one of the most commonly 
activated oncogenes in human cancer, and many tumors have 
been shown to be selectively sensitive to its inhibition. In 
other words, tumors with activated KRAS become ‘addicted’ 
to its oncogenic signaling. In contrast to the redundant 
pathways that safeguard embryonic development, tumor 
growth relies so heavily on the mutated KRAS pathway that 
its inhibition results in death and involution of the tumor [4].  
This so-called oncogene addiction has been an area of 
intense research for the development of targeted gene 
therapies, with the idea that tumors are uniquely sensitive to 
disruption of the signaling pathway to which they are 
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addicted [5]. However, in the case of KRAS, disrupting the 
signaling pathway has proven technically difficult for a 
variety of reasons [6]. In fact, KRAS itself is often held to be 
an ‘undruggable target’ for several reasons: unusually tight 
association between KRAS and GTP which prevents direct 
inhibition; compensatory protein modifications foil drugs 
targeting the lipid tags necessary for KRAS localization to 
the inner leaflet of the plasma membrane; and evolution of 
activating mutations in downstream KRAS effectors such as 
BRAF circumvent efforts to cut KRAS off at the legs [7]. 
Recently, several studies have attempted to determine 
whether KRAS-dependent tumors, resistant to frontal assault, 
can be outflanked using the principle of synthetic lethality to 
exploit a tumor’s addiction to non-oncogenic proteins. High 
throughput siRNA screens have been used to determine 
whether KRAS mutation rewires cellular pathways resulting 
in increased dependence of a tumor on other genetic 
pathways, such that inhibition of that pathway in 
combination with KRAS mutation would specifically confer 
lethality. A number of studies have shown that KRAS tumors 
depend on, for example, the cell cycle kinase PLK1, the 
transcription factor GATA2, and the NF-κB activator TBK1 
[8-11].  
Previous high-throughput screens have focused on using 
siRNAs or shRNAs to inhibit the expression of individual 
genes in KRAS mutant cancer cells. Our recent study has 
investigated the potential of microRNAs (miRNAs) to 
mediate synthetic lethality [12]. This approach presents an 
apparent advantage over the siRNA strategy: namely that a 
miRNA may post-transcriptionally inhibit the expression of 
dozens of target genes [13], especially when over-expressed, 
and can therefore influence the expression of gene networks 
rather than just individual genes [14]. We began by screening 
the effects of 879 human miRNAs on the viability of 
KRAS-Mutant HCT116 cells (colorectal cancer) compared to 
the isogenic KRAS-wild-type (WT) line. MiR-126 was 
observed to specifically reduce cell growth in KRAS-Mutant 
HCT116. This context-dependent effect was validated in 6 
additional colorectal cancer cell lines with differential KRAS 
mutation status. Moreover, the expression of miR-126 was 
significantly reduced in The Cancer Genome Atlas (TCGA) 
colorectal tumor samples with mutant KRAS (n=28) 
compared to wild type (n=57), indicating that 
down-regulation of miR-126 confers a selective advantage to 
KRAS mutant tumors. MiRNAs primarily act to reduce the 
stability and translation of their target mRNAs by binding to 
partially complementary sites in the mRNA 3’untranslated 
region (3’UTR) [15,16]. The KRAS-3’UTR does not contain 
any predicted miR-126 target sites, and indeed miR-126 
over-expression did not alter mutant KRAS mRNA or 
protein expression. This strongly suggested that the effect of 
Figure 1. A) We performed microarray gene expression profiling in an isogenic pair of HCT116-derived cell lines with either 
wild type (KRAS-WT) or mutant KRAS (KRAS-Mutant) following miR-126 mimic transfection. Although a highly similar set of 
mRNAs was significantly repressed in both cell types, the effects of miR-126 expression were strikingly different, with the 
wild-type cells growing normally and the KRAS mutant cells suffering a significant reduction in growth and tumorigenicity. B) 
We compared the genes significantly down-regulated by miR-126 to a list of KRAS synthetic lethal genes previously 
discovered by an RNAi screen. Nearly one-third of the RNAi candidates were significantly repressed by miR-126, 
suggesting that miR-126 over-expression has a synthetic lethal phenotype in KRAS-Mutant cells due to its silencing of 
genes uniquely required for the viability KRAS-Mutant cells. 
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miR-126 on the growth of KRAS mutant cancer cells was not 
due to direct inhibition of KRAS expression. In other words, 
the effect was more likely a reflection of a synthetic lethal 
interaction with KRAS than a withdrawal symptom of 
oncogene addiction.  
We then identified the target genes of miR-126 by 
microarray expression profiling combined with bioinformatic 
analysis of 3’UTR sequences for miR-126 seed matches. The 
direct targets of miR-126 were verified by 3’UTR reporter 
assays. Interestingly, we did not detect significant differences 
between the miR-126 regulated transcriptome in KRAS-WT 
and KRAS-Mutant cells despite the starkly different 
functional effects of miR-126 over-expression in these cell 
types (Fig. 1A). This observation raised the hypothesis that 
miR-126 targets genes that are synthetically lethal with 
mutant KRAS. To test this, we cross-referenced miR-126 
targets detected by microarray and 3’UTR assay with hits 
from previous KRAS synthetic lethality RNAi screens. We 
discovered that miR-126 mediates the repression of 22 genes 
that had previously been reported as synthetic lethal 
interactors with KRAS mutation in colon cancer, and we 
reasoned that these 22 genes were likely to be the effectors of 
the context dependent miR-126 phenotype (Fig. 1B). Many 
of these had roles in cell-cycle regulation, with the 
intersection of the KRAS synthetic lethal and miR-126 target 
gene sets being enriched for mitotic polo-like kinases. As 
expected from the results of the KRAS siRNA screen, we 
found that knockdown of miR-126 targets with siRNAs 
resulted in a significant repression of clonogenicity of 
KRAS-Mutant cells, but a greater, synergistic effect was 
observed with miR-126 transfection. We explain this as a 
consequence of the context-dependent regulation of a 
coherent gene network by miR-126 that is required for the 
viability of KRAS-Mutant cells. The effect of miR-126 on 
KRAS mutant cancers is likely to be due to down-regulation 
of polo-like kinase signaling: silencing of polo-like kinase 1 
(PLK1) has previously been shown to be synthetically lethal 
with KRAS mutations [9]. In addition to PLK1, we also 
showed that several genes such as UBQLN2 and SLC39A6 
not involved in canonical RAS signaling played a role in the 
selective growth suppression mediated by miR-126 in 
KRAS-Mutant cells. 
The therapeutic promise of synthetic lethal approaches to 
cancer treatment is easy to see: targeting a specific genetic 
vulnerability of cancer would likely constitute a significant 
improvement in therapeutic index (dose required for therapy 
divided by dose required for toxicity) relative to conventional 
chemotherapy [1]. As miRNAs slowly but surely make their 
way from the bench to the clinic [17], it will be important to 
find miRNAs that exhibit context-dependent specificity for 
targeting cancer cell growth. Our work on miR-126 and 
mutant KRAS has uncovered at least one such miRNA. 
Several other miRNAs in our screen also seemed to have a 
selective inhibitory effect on KRAS mutant cells. For 
example, miR-122 was a very potent inhibitor of HCT116 
KRAS-Mutant cell growth, but was not endogenously 
expressed in HCT116 KRAS-WT or KRAS-Mutant cells. 
We omitted miR-122 from further analysis, reasoning that it 
was unlikely to play a significant role in the biology of 
HCT116 cells, but it may yet be an effective biomolecule for 
therapeutic inhibition of KRAS-mutant tumors. It is likely 
that a similar approach will uncover more KRAS synthetic 
lethal miRNAs as well as miRNAs that selectively target 
other tumor types or oncogenic networks. 
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